ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
ttn2
|
821 |
206K |
3 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
821
|
206K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Date of AGM and Closing Date for Director Nominations
|
|
ttn2
|
71 |
20K |
1 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
71
|
20K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Appendix 4E & Annual Report
|
|
ttn2
|
30 |
12K |
16 |
30/08/23 |
30/08/23 |
ASX - By Stock
|
30
|
12K
|
16
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
10 |
09/06/23 |
09/06/23 |
General
|
10K
|
3.7M
|
10
|
|
ASX - By Stock
|
ADN |
Re:
Ann: Cancellation of offtake with Asia Material Resources Ltd
|
|
ttn2
|
200 |
71K |
5 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
200
|
71K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
RAC Investor Hub Q&A
|
|
ttn2
|
106 |
30K |
4 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
106
|
30K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ttn2
|
1.6K |
570K |
1 |
16/04/23 |
16/04/23 |
ASX - By Stock
|
1.6K
|
570K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race releases cardioprotection market potential data
|
|
ttn2
|
239 |
95K |
7 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
239
|
95K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race releases cardioprotection market potential data
|
|
ttn2
|
239 |
95K |
10 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
239
|
95K
|
10
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
17 |
03/04/23 |
03/04/23 |
General
|
10K
|
3.7M
|
17
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
7 |
31/03/23 |
31/03/23 |
General
|
10K
|
3.7M
|
7
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
4 |
31/03/23 |
31/03/23 |
General
|
10K
|
3.7M
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Pause in Trading
|
|
ttn2
|
42 |
12K |
4 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
42
|
12K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
12 |
22/11/22 |
22/11/22 |
ASX - By Stock
|
2.0K
|
666K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Develops Improved IV Formulation of Zantrene
|
|
ttn2
|
90 |
35K |
24 |
28/09/22 |
28/09/22 |
ASX - By Stock
|
90
|
35K
|
24
|
|
ASX - By Stock
|
SRN |
Re:
Options
|
|
ttn2
|
170 |
52K |
1 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
170
|
52K
|
1
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
2 |
02/05/22 |
02/05/22 |
General
|
10K
|
3.7M
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Supply Agreement for EMD AML Trial
|
|
ttn2
|
75 |
31K |
3 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
75
|
31K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Supply Agreement for EMD AML Trial
|
|
ttn2
|
75 |
31K |
0 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
75
|
31K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Compelling Zantrene Preclinical Kidney Cancer Data
|
|
ttn2
|
99 |
35K |
12 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
99
|
35K
|
12
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2022 and beyond
|
|
ttn2
|
2.9K |
1.3M |
0 |
13/01/22 |
13/01/22 |
ASX - By Stock
|
2.9K
|
1.3M
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Appendix 3Y - Dr Daniel Tillett
|
|
ttn2
|
36 |
11K |
21 |
13/12/21 |
13/12/21 |
ASX - By Stock
|
36
|
11K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race online Q&A investor briefing invitation
|
|
ttn2
|
126 |
37K |
6 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
126
|
37K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
8 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
2.0K
|
666K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Expanded Heart Protection Discovery for Zantrene
|
|
ttn2
|
386 |
131K |
12 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
386
|
131K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
9 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
2.0K
|
666K
|
9
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ttn2
|
20K |
6.9M |
2 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
20K
|
6.9M
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race investor briefing & updated presentation
|
|
ttn2
|
334 |
87K |
26 |
05/12/21 |
05/12/21 |
ASX - By Stock
|
334
|
87K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
10 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
2.0K
|
666K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
33 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
2.0K
|
666K
|
33
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
8 |
27/11/21 |
27/11/21 |
ASX - By Stock
|
2.0K
|
666K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ttn2
|
2.0K |
666K |
53 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
2.0K
|
666K
|
53
|
|
ASX - By Stock
|
ADN |
Re:
General comments/chat
|
|
ttn2
|
43K |
20M |
2 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
43K
|
20M
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: AGM Presentations
|
|
ttn2
|
82 |
25K |
2 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
82
|
25K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Trading Halt
|
|
ttn2
|
218 |
65K |
3 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
218
|
65K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Trading Halt
|
|
ttn2
|
218 |
65K |
3 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
218
|
65K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Breakthrough Zantrene Heart Protection Discovery
|
|
ttn2
|
366 |
119K |
17 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
366
|
119K
|
17
|
|
ASX - By Stock
|
RAC |
Re:
Ann: University of Wollongong R&D Collaboration
|
|
ttn2
|
167 |
41K |
22 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
167
|
41K
|
22
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
11 |
10/11/21 |
10/11/21 |
General
|
10K
|
3.7M
|
11
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
8 |
08/11/21 |
08/11/21 |
General
|
10K
|
3.7M
|
8
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
7 |
07/11/21 |
07/11/21 |
General
|
10K
|
3.7M
|
7
|
|
ASX - By Stock
|
ADN |
Re:
Nearest to pin competition ( No prize) :)
|
|
ttn2
|
61 |
20K |
3 |
06/11/21 |
06/11/21 |
ASX - By Stock
|
61
|
20K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Companion Diagnostic Study Initiated with UON
|
|
ttn2
|
120 |
32K |
10 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
120
|
32K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ttn2
|
1.6K |
570K |
11 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
1.6K
|
570K
|
11
|
|
Charts
|
VBS |
Re:
VBS Chart and TA
|
|
ttn2
|
5 |
2.4K |
0 |
19/10/21 |
19/10/21 |
Charts
|
5
|
2.4K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Preclinical & Clinical Programs Update
|
|
ttn2
|
186 |
56K |
35 |
03/10/21 |
03/10/21 |
ASX - By Stock
|
186
|
56K
|
35
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ttn2
|
10K |
3.7M |
13 |
23/09/21 |
23/09/21 |
General
|
10K
|
3.7M
|
13
|
|
ASX - By Stock
|
RAC |
Re:
Cancer Inhibitor News
|
|
ttn2
|
55 |
19K |
2 |
11/09/21 |
11/09/21 |
ASX - By Stock
|
55
|
19K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit signs first commercial deal with US-based SkyWater
|
|
ttn2
|
698 |
277K |
1 |
09/09/21 |
09/09/21 |
ASX - By Stock
|
698
|
277K
|
1
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ttn2
|
20K |
6.9M |
9 |
05/09/21 |
05/09/21 |
ASX - By Stock
|
20K
|
6.9M
|
9
|
|